T. Rowe Price Associates
BCYC

T. Rowe Price Associates’s Bicycle Therapeutics BCYC Stock Holding History

T. Rowe Price Associates’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.83M Sell
902,150
-126,093
-12% -$578K ﹤0.01% 1710
2026
Q1 		$4.77M Sell
1,028,243
-143,544
-12% -$820K ﹤0.01% 1439
2025
Q4 		$8.3M Sell
1,171,787
-213,007
-15% -$1.57M ﹤0.01% 1266
2025
Q3 		$10.7M Sell
1,384,794
-83,599
-6% -$631K ﹤0.01% 1210
2025
Q2 		$10.2M Sell
1,468,393
-68,191
-4% -$543K ﹤0.01% 1106
2025
Q1 		$13M Sell
1,536,584
-48,543
-3% -$572K ﹤0.01% 1058
2024
Q4 		$22.2M Sell
1,585,127
-136,913
-8% -$2.93M ﹤0.01% 972
2024
Q3 		$39M Buy
1,722,040
+923,539
+116% +$21.3M ﹤0.01% 819
2024
Q2 		$16.2M Buy
798,501
+396,855
+99% +$8.97M ﹤0.01% 1007
2024
Q1 		$10M Buy
401,646
+124,809
+45% +$2.65M ﹤0.01% 1111
2023
Q4 		$5.01M Sell
276,837
-316,216
-53% -$5.23M ﹤0.01% 1208
2023
Q3 		$11.9M Buy
593,053
+295,768
+99% +$6.76M ﹤0.01% 1039
2023
Q2 		$7.59M Sell
297,285
-20,791
-7% -$483K ﹤0.01% 1113
2023
Q1 		$6.77M Sell
318,076
-20,657
-6% -$518K ﹤0.01% 1121
2022
Q4 		$10M Sell
338,733
-78,607
-19% -$2.11M ﹤0.01% 1054
2022
Q3 		$9.71M Sell
417,340
-3,921
-0.9% -$93.3K ﹤0.01% 1070
2022
Q2 		$7.07M Sell
421,261
-264,615
-39% -$5.58M ﹤0.01% 1375
2022
Q1 		$30.1M Sell
685,876
-110,138
-14% -$5.14M ﹤0.01% 1125
2021
Q4 		$48.5M Buy
+796,014
New +$43.9M ﹤0.01% 1018

Other funds holding BCYC

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
GP
GSK plc London $602M AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

T. Rowe Price Associates's BCYC Position: Q2 2026 in Review

T. Rowe Price Associates reduced its Bicycle Therapeutics (BCYC) stake by 12% in Q2 2026, selling an estimated $578K and leaving 902,150 shares worth $3.83M. The position accounts for ﹤0.01% of the portfolio, ranked #1710.

T. Rowe Price Associates first reported a position in BCYC in Q4 2021 and has held it in 19 quarters since. The position peaked at $48.5M in Q4 2021. 104 funds tracked by Wall St. Rank hold BCYC as of Q2 2026.

  • T. Rowe Price Associates held 902,150 shares of Bicycle Therapeutics worth $3.83M as of Q2 2026.
  • T. Rowe Price Associates sold 126,093 Bicycle Therapeutics shares in Q2 2026, an estimated $578K.
  • Bicycle Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #1710 holding.
  • T. Rowe Price Associates first reported a position in Bicycle Therapeutics in Q4 2021 and has held it in 19 quarters since.
  • T. Rowe Price Associates's Bicycle Therapeutics position peaked at $48.5M in Q4 2021.
  • 104 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.